Exuberance Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 26.00 Cr
as on 13-01-2025
- Paid Up Capital ₹ 25.02 Cr
as on 13-01-2025
- Company Age 1 Year 9 Months
- Open Charges ₹ 140.00 Cr
as on 13-01-2025
About Exuberance Pharmachem
The Company's status is Active It's a company limited by shares with an authorized capital of Rs 26.00 Cr and a paid-up capital of Rs 25.02 Cr.
The company currently has active open charges totaling ₹140.00 Cr.
Venkata Komaragiri, Subrata Dasgupta, Subhas Banerjee, and Two other members serve as directors at the Company.
- CIN/LLPIN
U46497TS2023PTC171840
- Company No.
171840
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Apr 2023
- Date of AGM
-
- Date of Balance Sheet
-
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Exuberance Pharmachem?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkata Komaragiri  | Additional Director | 16-Aug-2024 | Current |
| Subrata Dasgupta | Director | 11-Apr-2023 | Current |
| Subhas Banerjee | Director | 11-Apr-2023 | Current |
| Surendra M | Additional Director | 09-Jul-2024 | Current |
| Ram Thumma | Additional Director | 09-Jul-2024 | Current |
Financial Performance of Exuberance Pharmachem.
Enhance accessibility to Exuberance Pharmachem's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Exuberance Pharmachem?
Unlock access to Exuberance Pharmachem's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Discovery Knowledge Systems LimitedActive 13 years 6 monthsSubrata Dasgupta and Subhas Banerjee are mutual person
Falma Laboratories Private LimitedActive 39 years 1 monthSubrata Dasgupta and Subhas Banerjee are mutual person
Prudential Investment Ltd.Active 40 years 11 monthsSubrata Dasgupta and Subhas Banerjee are mutual person
- Prudential Stock Broking Services LtdActive 34 years 2 months
Subrata Dasgupta and Subhas Banerjee are mutual person
- Eduexel Infotainment LimitedActive 34 years 4 months
Subrata Dasgupta and Subhas Banerjee are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 24 Aug 2024 | ₹140.00 Cr | Open |
How Many Employees Work at Exuberance Pharmachem?
Unlock and access historical data on people associated with Exuberance Pharmachem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Exuberance Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Exuberance Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.